Mirabegron (Betmiga▼): risk of severe hypertension and associated cerebrovascular and cardiac events

Mirabegron is now contraindicated in patients with severe uncontrolled hypertension; advice about regular monitoring is being introduced because of cases of severe hypertension.


Letters sent to healthcare professionals in September 2015

A letter was sent to healthcare professionals about mirabegron for symptomatic treatment of urgency, increased micturition frequency, or urgency incontinence.


Posted on the UK MHRA website on 14 October 2015